[Image credit DNDi]
AfricaHealth

AU Strengthens Collaboration with Drugs for Neglected Diseases initiative

The African Union (AU) Commission’s Department of Health entered into a collaboration agreement with the Drugs for Neglected Diseases Initiative (DNDi) to bolster Africa’s fight against neglected tropical diseases or NTDs.

The memorandum of understanding signed on Monday aims to advance policy advocacy, research and development (R&D), and access to treatments for NTDs across the continent.

NTDs affect over a billion people globally, with Africa bearing a significant portion of this burden. Diseases such as leishmaniasis, sleeping sickness, and river blindness disproportionately impact the continent’s most vulnerable populations, hindering socio-economic development and quality of life.

The newly signed MoU, according to the AU, aligns with the Common African Position on NTDs, which outlines a strategic vision to control, eliminate, and eradicate these diseases by 2030.

Minata Samate Cessouma, Commissioner for Health, Humanitarian Affairs and Social Development, called the partnership with non-governmental medical research organisation DNDi as a pivotal step towards eradicating neglected tropical diseases in Africa.

“We are committed to developing and delivering effective treatments to the most vulnerable, promoting R&D and innovation for new technologies for NTDs and climate-sensitive diseases in line with the AU’s Agenda 2063,” stated Cessouma.

DNDi, the AU says, has a strong track record of providing safe, effective, and affordable treatments for neglected patients, and has developed 13 treatments for six deadly diseases since its establishment in 2003.

Its Executive Director Dr Luis Pizarro stated that neglected diseases have long become the cause of immense suffering to vulnerable communities across the continent.

“This partnership with the African Union is about changing that by bringing science and policy action together to drive innovation and ensure that effective treatments reach patients in need and on time,” said Dr Pizarro.

The partnership will focus on jointly advancing the discovery and development of new treatments for NTDs prevalent in Africa through collaborative R&D efforts.

It will also prioritise capacity building by strengthening the capabilities of African health institutions and professionals in managing and researching NTDs, as well as promote advocacy and policy development to support sustainable access to treatments and integrate NTD initiatives into national health agendas.